Vaxcyte annual total assets
2019
2020
2021
2022
2023
2024
2025
Vaxcyte Total Assets Growth & History (PCVX)
Vaxcyte's total assets was $3.00B for fiscal 2025.
View full Vaxcyte company overviewVaxcyte annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.00B | −$508.6M | −14.48% |
| 2024 | 2024-12-31 | $3.51B | $2.10B | +149.40% |
| 2023 | 2023-12-31 | $1.41B | $401.7M | +39.93% |
| 2022 | 2022-12-31 | $1.01B | $681.8M | +210.23% |
| 2021 | 2021-12-31 | $324.3M | −$68.5M | −17.43% |
| 2020 | 2020-12-31 | $392.8M | $327.1M | +497.93% |
| 2019 | 2019-12-31 | $65.7M | — | — |
Vaxcyte quarterly total assets
Q4.19
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.14B | −$167.2M | −5.06% |
| Q1 2026 | 2026-03-31 | $3.35B | −$29.8M | −0.88% |
| Q4 2025 | 2025-12-31 | $3.00B | −$508.6M | −14.48% |
| Q3 2025 | 2025-09-30 | $3.17B | −$388.1M | −10.90% |
| Q2 2025 | 2025-06-30 | $3.31B | $1.22B | +58.36% |
| Q1 2025 | 2025-03-31 | $3.38B | $1.29B | +61.53% |
| Q4 2024 | 2024-12-31 | $3.51B | $2.10B | +149.40% |
| Q3 2024 | 2024-09-30 | $3.56B | $2.06B | +137.94% |
| Q2 2024 | 2024-06-30 | $2.09B | $584.4M | +38.89% |
| Q1 2024 | 2024-03-31 | $2.09B | $1.08B | +107.44% |
| Q4 2023 | 2023-12-31 | $1.41B | $401.7M | +39.93% |
| Q3 2023 | 2023-09-30 | $1.50B | $1.08B | +263.06% |
| Q2 2023 | 2023-06-30 | $1.50B | $1.09B | +265.10% |
| Q1 2023 | 2023-03-31 | $1.01B | $605.4M | +150.34% |
| Q4 2022 | 2022-12-31 | $1.01B | $681.8M | +210.23% |
| Q3 2022 | 2022-09-30 | $412.1M | $58.0M | +16.38% |
| Q2 2022 | 2022-06-30 | $411.6M | $53.6M | +14.96% |
| Q1 2022 | 2022-03-31 | $402.7M | $20.4M | +5.33% |
| Q4 2021 | 2021-12-31 | $324.3M | −$68.5M | −17.43% |
| Q3 2021 | 2021-09-30 | $354.1M | −$49.7M | −12.32% |
| Q2 2021 | 2021-06-30 | $358.1M | −$58.2M | −13.98% |
| Q1 2021 | 2021-03-31 | $382.4M | — | — |
| Q4 2020 | 2020-12-31 | $392.8M | $327.1M | +497.93% |
| Q3 2020 | 2020-09-30 | $403.8M | — | — |
| Q2 2020 | 2020-06-30 | $416.2M | — | — |
| Q4 2019 | 2019-12-31 | $65.7M | — | — |
Vaxcyte total assets trends
Over the last five fiscal years, Vaxcyte's total assets increased from $392.8M to $3.00B, a change of $2.61B. The latest reported quarter, Q2 2026, shows $3.14B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vaxcyte source filings ↗